Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 353 | 76 | 273 |
| Samples | 302 | 71 | 229 |
| Peptides | 223 | 48 | 181 |
Function
ERV3-1 · Endogenous retrovirus group 3 member 1, envelope
This gene contains sequence derived from endogenous retrovirus, and is therefore similar to multiple other loci in the genome. Transcripts at this locus encode a conserved protein with a predicted signal peptide and similarity to the Env polyprotein. This protein is overexpressed in colorectal and other cancers. [provided by RefSeq, Jan 2017].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000394323 | Q14264 | 353 | 223 |
Gene Properties
Recurrent Mutations
All 223 amino-acid changes on canonical ENST00000394323 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ERV3-1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ERV3-1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Endometrial Carcinoma | 2/42 5% | 18/612 3% |
| Melanoma | 3/210 1% | 32/1899 2% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 10/810 1% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 13/1390 1% |
| Non-Cancerous | 0/104 0% | 11/830 1% |
| Head and Neck Carcinoma | 5/85 6% | 12/1574 1% |
| Bladder Carcinoma | 4/58 7% | 6/956 1% |
| Gastric Carcinoma | 0/74 0% | 18/1809 1% |
| Colorectal Carcinoma | 12/143 8% | 20/3239 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 19/2550 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Cervical Carcinoma | 2/35 6% | 1/422 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 0/94 0% | 8/1515 1% |
| Neuroblastoma | 5/87 6% | 2/1331 0% |
| Breast Carcinoma | 2/144 1% | 14/3264 0% |
| Neuroendocrine Tumour | 3/154 2% | 0/577 0% |
| Hepatocellular Carcinoma | 2/46 4% | 7/2210 0% |
| Glioma | 2/52 4% | 5/2127 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 8/2534 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Esophageal Carcinoma | 1/23 4% | 1/769 0% |
| Other Blood Cancers | 4/61 7% | 2/2725 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 2/1592 0% |
Mutation Distribution
Where ERV3-1 is mutated · all tissues, split by cell line vs tissue
How many mutations in ERV3-1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 353 mutations in ERV3-1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|